Gilead Sciences, Inc.
NEWS
Early tests of Regeneron’s antibody cocktail show it isn’t as effective against Omicron while a separate tests of Eli Lilly’s antibody cocktail also demonstrated the same.
With the Thanksgiving holiday upon us, BioSpace felt it was important to give thanks for some of the positive things that have happened this year. And there are many!
Both Gilead Sciences and Merck announced they were pausing a Phase II trial of islatravir and lenacapavir in HIV.
“I hope to thread the needle between pricing responsibly and achieving profitability,” Jarrett said.
Gilead Sciences announced it exercised its options to three of Arcus Biosciences’ programs. Two are anti-TIGIT molecules, domvanalimab and AB308, and the other is etrumadenant and quemliclustat.
Vaccinations will be required by January 4 under the new White House plan.
Shoreline Biosciences secured $140 million in financing to accelerate the growth of its induced pluripotent stem cells (iPSC)-based immunotherapies and support the expansion of its manufacturing capabilities.
BlueSphere Bio aims to overcome challenges in the CAR T space with a precision approach to T cell therapy.
Gilead Sciences has one of the most robust HIV pipelines in the world. New real-world data from the ongoing BICSTaR study demonstrates benefits of HIV drug Biktarvy.
JOBS
IN THE PRESS